Advancements in stem cell research continue to shed light on the potential for how stem cells can be used for various clinical applications, including cell replacement therapies, immunomodulatory therapies, and many others. Whether you are developing an induced pluripotent stem cell (iPSC) based therapy or adult stem cell therapy, Thermo Fisher Scientific has the solutions to advance your research to the clinic and beyond. Advancing your stem cell therapy to the clinic requires careful raw material selection because the starting materials can significantly impact the properties of your final stem cell therapy product. We offer high-quality stem cell reagents, media, and solutions for a variety of applications.
The first step in iPSC–derived therapy generation is isolation and cultivation of the donor’s somatic cells. The cell type used for reprogramming is often determined by availability of donor tissue, and the ultimate purpose for the iPSCs being generated. Having a robust and versatile reprogramming solution that can be used across a wide range of cell types and origins can help manufacturers overcome some of the variables encountered due to donor cell health, streamlining the manufacturing process.
Successful generation of iPSCs can depend on many factors including the age, health and disease status of the donor, the viability and proliferation rate of the isolated somatic cells, and the cell type. It is important to choose a reprogramming system which can help to overcome some of these potential challenges.
Sendai virus–based CytoTune reprogramming kits are one of the most versatile and robust commercially available reprogramming systems and can be used to reprogram a wide range of cell types and origins. Additionally, the CTS CytoTune-iPS 2.1 Sendai Reprogramming Kit is the first off-the-shelf reprogramming system designed for clinical and translational research.
Patient-derived iPSCs offer exciting potential for both cell therapy and in vitro disease modeling by enabling access to cell populations that are otherwise unavailable from living donors. With the recent discovery of site-specific gene editing, fully harnessing and leveraging this capability is fast approaching. iPSCs can be genetically altered at a specific locus using genome engineering tools such as CRISPR or TALEN. In addition to genome editing tools we also offer viral transduction solutions, lipid-based transfection reagents and electroporation tools.
Considerations for banking PSCs Generation of a robust PSC bank can be an important precursor to downstream cell therapy applications. Towards this, utilizing a cryomedium enables large quantities of cells to be safely placed into long-term cryopreservation.
Recovery of cryopreserved PSCsCareful handling of cryopreserved PSCs is critical to support post-thaw recovery while minimizing cell death. To reduce stress from osmotic shock when thawing PSCs in cryomedium, dropwise addition of fresh culture medium along with specialized supplements can enhance PSC attachment and recovery.
PSC growth and expansionWhen expanding PSCs in routine culture, maintenance of pluripotency, trilineage differentiation potential and karyotypic stability are essential for success in downstream cell therapy applications.
Download the PSC Handbook to learn more about the latest tools, resources, applications and more, to support every step of your PSC workflow.
iPSCs can generate virtually unlimited numbers of differentiated cell types, including neurons, cardiomyocytes, and potentially any other cell type in the body. These differentiated cells can be used in a range of applications including basic research, drug discovery, or future therapeutic applications. Stem cell differentiation requires standardized culture methods to help ensure reproducible and reliable results. Gibco media, supplements, and substrates provide you with an easy-to-use, flexible set of tools for targeted differentiation to your desired cell lineage. Our differentiation portfolio helps simplify your workflow and provides you with more control, enabling for fast, more efficient systems.
To view the complete differentiation portfolio, go to thermofisher.com/differentiation.
Differentiation of iPSCs can be studied using EVOS Cell Imaging Systems.
Hematopoietic stem cells (HSCs) and mesenchymal stromal cells (MSCs, also known as mesenchymal stem cells) are readily available from a variety of tissue sources and show potential to address many unmet medical needs including blood disorders and cancers (HSCs), tissue reconstruction and graft-versus-host-disease (MSCs).
Mesenchymal stem cells can be genetically altered using lipid-base transfection, electroporation, viral approaches or genome engineering tools such as CRISPR or TALEN. Methods may vary by cell type and application, so a broad array of gene transfer tools is available for your needs.
Prior to cell banking, a cell count should be performed. Total cell count should be determined in a manual, semi-automated or au
